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Introduction: RECIST criteria serve as the gold standard method to monitor treatment 
efficacy in lung cancer. However, time-intervals between consecutive CT scans might 
be too long to allow early identification of treatment failure. This study examines the 
use of breath sampling to monitor responses to anti-cancer treatments in patients with 
advanced lung cancer.  
Methods: 143 breath samples were collected from 39 patients with advanced lung 
cancer. The exhaled breath signature, determined by GC-MS1 and nanomaterial-
based array of sensors, was correlated with the response to therapy assessed by 
RECIST: Complete Response (CR), Partial Response (PR), Stable Disease (SD), or 
Progressive Disease (PD).   
Results: GC-MS1 analysis identified 3 volatile organic compounds (VOCs) as 
significantly indicating disease control (PR/SD), with one of them also significantly 
discriminating PR/SD from PD. The nano-array had the ability to monitor changes in 
tumor response across therapy, also indicating any lack of further response to therapy. 
Using one sensor analysis, 59% of the follow-up samples were identified correctly. 
There was 85% success in monitoring disease control (SD/PR).    
Conclusion: Breath analysis, using mainly the nano-array, may serve as a surrogate 
marker for the response to systemic therapy in lung cancer. As a monitoring tool, it can 
provide the oncologist with a quick bed-side method of identifying a lack of response 
to an anti-cancer treatment. This may allow quicker recognition than the current 
RECIST analysis. Early recognition of treatment failure could improve patient care. 
 
Keywords: Lung Cancer; Early Detection; Exhale Breath; Biomarkers.  
  
                                                            
1 gas‐chromatography/mass‐spectrometry 
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INTRODUCTION 
Monitoring treatment efficacy by non-imaging bedside methods is crucial in lung 
cancer, where The Response Evaluation Criteria in Solid Tumors (RECIST) 
assessment is performed every 2-3 cycles and sometimes even less frequently. A non-
imaging method is particularly important when disease may respond to treatment, 
although the target lesions increase in size (pseudo-progression), as sometimes 
occurs with immunotherapies. Therefore, understanding treatment efficacy and its 
failure early in the course of therapy is extremely important and may improve treatment 
outcome [1-3]. To date, imaging has been primarily used in the assessment of 
response to anti-cancer treatment in lung cancer patients, Computerized Tomography 
(CT) being the mainstay. The RECIST [1-4] approach categorizes the total response 
into one of 4 groups: complete response (CR), partial response (PR), stable disease 
(SD) or progressive disease (PD; see 'Methods') [4]. However, time-intervals between 
consecutive CT scans might be too long to allow early identification of treatment failure; 
moreover, scans are expensive and not always available.  
An emerging approach that shows great promise in monitoring lung cancer (LC) 
treatment is based on volatile organic compounds (VOCs) emitted in breath samples 
[5-14]. These VOCs emanate from the membrane of the cancer cells and/or from its 
surrounding tissues to the blood stream as a result of inflammation and oxidative 
stress, being excreted by diffusion across the pulmonary alveolar membrane and 
exhaled through the breath [15-17]. The role of VOCs as markers in various lung 
diseases, including cancer, has already been evaluated. Analysis of exhaled breath 
has already successfully distinguished asthmatic patients from healthy individuals [18, 
19], delineated COPD [20, 21], differentiated between patients with LC and healthy 
patients with non-cancerous lung nodules [5, 6, 11, 14, 16, 22-27] , and between 
subtypes of lung cancer [28]. Broza et al [29] have shown that breath analysis can be 
used for short-term follow-up after LC-resection. However, changes in VOCs in LC 
patients throughout the course of their disease and under systemic anti-cancer therapy 
have yet to be studied. 
This study investigated the possibility of breath VOC signature being a marker for 
treatment efficacy in advanced lung cancer patients. Exhaled breath analysis is a 
simple non-invasive method that could allow the oncologist to recognize disease status 
during the course of treatment. In this prospective study, consecutive breath samples 
were collected from patients receiving systemic therapy for advanced stage LC. The 
samples were categorized into different response groups by matching them to their 
evaluation from sequential CT scans of the response of tumors to treatment. Several 
comparisons were conducted to identify differences in VOC patterns between the 
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response groups. Two separate breath-analysis methods were used for this purpose - 
gas chromatography with mass spectrometry (GC-MS) and chemical nano-arrays (NA-
NOSE). While GC-MS allowed the identification and quantification of a wide variety of 
separate breath VOCs, the NA-NOSE provided a sensor-based discrimination 
between the groups without regard to the nature and composition of the breath VOCs. 
PATIENTS AND METHODS 
Patients  
Between May 2012 and June 2013, 39 patients diagnosed with stage III/IV lung cancer 
and scheduled for systemic therapy (chemotherapy or targeted therapy) at the 
Thoracic Oncology Unit of the Sheba Medical Center, Israel, were enrolled. Approval 
was obtained from the ethics committee of the Sheba Medical Center [NCT01386203]. 
All patients were given a written and verbal explanation about the study prior to their 
enrollment, and had signed a written consent of participation form. Each patient was 
interviewed regarding personal data, smoking habits and relevant medical history. 
Clinical characteristics of the study population are summarized in Table 1. 
Breath collection 
Exhaled alveolar breath samples were collected from patients in a controlled manner. 
The first breath sample was taken from each patient prior to and close to the start of 
the first systemic therapy cycle. Repeat samples were collected prior to and adjacent 
to subsequent cycles, or during follow-up meetings with the attending physician. 
Patients were asked to refrain from smoking, and withhold alcohol and food 
consumption for 2 h prior to breath sampling. Alveolar exhaled breath was collected in 
chemically inert Mylar bags (Eco Medics, Duernten, Switzerland) in a controlled way 
after a 1 min procedure of a lung washout procedure described elsewhere [10, 11, 23]. 
Breath collection was a single-step process that did not require changing between the 
dead space and alveolar breath bags. The content of each bag was transferred 
immediately through an offline procedure to a coded Tenax® sorbent tube (SKC Inc., 
Eighty Four, PA). The tubes were stored at 4ºC in a clean environment and transported 
to the Laboratory for Nanomaterial-Based Devices (Technion, Israel) for analysis by 
both GC-MS and the sensors’ nano-array.  
 
 (Figure 1) 
Methods 
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Chemical analysis of breath samples  
GC-MS were used to identify the exact composition and seek specific informative 
breath VOCs [7, 71, 87]. Gas chromatography uses a helium stream that carries the 
sample through a long heated capillary column to separate molecules in the VOCs 
mixture according to their volatility, more volatile compounds travelling faster than less 
volatile ones. Due to the difference in the chemical properties in the mixture, each 
molecule has a different exit time from the column (the retention time). The mass 
spectrometer determines molecular mass and chemical structure of the VOCs after 
being broken up into characteristic fragments and ionized. In the mass analyzer, the 
ions are filtered by an electric field according to their mass/charge (m/z) ratio. The 
retention time and the mass charge ratio are used to identify the compounds by a 
spectral library in the GC software, thus reducing the possibility of error in identification. 
Certain identification could be done only by the analysis of pure standards to validate 
the supposed identity by the system [88]. (For more details, see Supplementary 
Information (SI), section 1.2) 
Nanoarray Analysis of Breath Samples 
The nanomaterial-based sensor array used to analyze the breath samples contained 
40 cross-reactive, chemically diverse chemiresistors that were based on 2 types of 
nanomaterials: (i) organically stabilized spherical gold nanoparticles (GNPs, core 
diameter 3-4 nm), and (ii) single wall carbon nanotubes (SWCNTs) capped with 
polycyclic aromatic hydrocarbon (PAH). The chemical diversity of the sensors was 
achieved through different organic functionalities. The GNP and SWCNT/PAH or 
SWCNT/HBC sensors responded rapidly and reversibly when exposed to typical 
VOCs in the breath [24, 25].  We also confirmed that they are only weakly responsive 
to water [23, 30, 31]. (For further details, see SI, section 1.3) 
 
Study Design 
Evaluation of patients' response to treatment  
Patients went through periodical CT scans to evaluate their response to treatment. 
Referral to scans was decided upon by the attending physician, regardless of the 
study. CT scans were reviewed centrally by an expert radiologist. The patient's 
response was categorized from each CT scan relative to the previous scan [26] as:  
(i) Complete response (CR) - disappearance of all target lesions. 
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(ii) Partial Response (PR) – a 30% decrease in the sum of the longest diameters 
of target lesions. 
(iii) Progressive Disease (PD) – a 20% increase in the sum of the longest 
diameters of target lesions. 
(iv) Stable Disease (SD) - small changes not meeting other criteria. 
The first breath sample of each patient was taken as the Baseline Sample (BL).  
Subsequent samples were matched with the next proximal CT scan of the patient, and 
categorized according to one of the 4 abovementioned groups. Analysis included only 
breath samples that met one or more of the following criteria: (1) a breath sample that 
was taken up to 3 months prior to the last available CT scan; (2) a breath sample that 
was taken up to 3 weeks after the last available CT scan. If more than one CT scan 
was available that fulfilled the criteria, the sample was categorized by the latest scan. 
Three main groups were defined for comparison after categorizing the breath samples 
by response: 
(i) Baseline samples 
(ii) Disease Control (DC) - composed of PR+SD samples, which both indicated a 
positive response to treatment (i.e. no worsening of the disease) 
(iii)  PD samples 
The clinical status of each event was defined relative to the previous disease status. 
 
Statistical analysis 
The breath samples were analyzed using 2 independent approaches in 2 phases. In 
the first phase, a GC-MS system operating with a post-run analysis program (GCMS 
solutions version 2.53SU1, Shimadzu Corporation, Germany) was used to find 
statistically different concentrations between the 4 groups. Compounds were 
tentatively identified through spectral library matching (Compounds Lbrary of the 
National Institute of Standards and Technology, Gaithersburg, MD 20899-1070, USA). 
In the second phase, breath samples were characterized with an array of 
nanomaterial-based sensors, combined with multivariate discriminant function analysis 
(DFA) [34] as statistical pattern recognition algorithms (SI, section 1.4), with the aim of 
identifying the “breath print” of the different defined groups. The accuracy of DFA was 
confirmed by employing leave-one-out cross validation.  
The Wilcoxon test was used to find statistically significant differences in the average 
abundance of the VOC's for the different groups (SI, section 1.5). Data classification 
was attempted by Discriminant Factor Analysis (DFA). The accuracy of DFA was 
further confirmed by leave-one-out cross-validation, and sensitivity, specificity and 
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accuracy were calculated. Statistical analysis was carried out using SAS JMP, Version 
10.0 (SAS Institute Inc., Cary, NC, USA, 1989-2005). 
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RESULTS:  
A summary of the clinical data of each of the advanced LC patients who participated 
are given in Table 1. Approximately 80% were males, mean age 62 ± 7.2 years.  
Former smokers accounted for 69% (average 52 ± 24 pack years); 18% were current 
smokers (average 86 ± 54 pack years), and 13% had never been smokers (Table 1). 
Most (85%) of the patients had Non-Small Cell Lung Cancer (NSCLC) with different 
histological diagnoses (squamous cell, adenocarcinoma and “not otherwise specified” 
(NOS)). Only 15% of the patients had Small Cell Lung Cancer (SCLC). (Table 1). 
Stage 3 patients had also been treated with radiotherapy, although outside the study 
period. About 82% of the patients received chemotherapy as first-line therapy, the most 
common protocol being a combination of Cisplatin/Carboplatin and Pemetrexed 
(Alimta). About 20% of the patients were treated by EGFR/ALK TKIs (EGFR: 7 ALK: 
1).  
 
Breath samples (143 in total) from 39 patients were collected, ranging from 1 to 12 per 
patient (average 3.7). A total of 135 samples meeting the inclusion criteria were 
analyzed. The average time between subsequent breath samples was 6.7 (± 6.3) 
weeks. The first sample was taken on 03/15/2012, and the last sample on 06/27/2013. 
The average time of follow-up was 18.1 (±17.7) weeks (range 0.1-64 weeks).    
BL numbered 39 samples, while there were 47 samples in the PR group, 38 in the SD 
group, and 11 in the PD group (Table 2). 
Chemical analysis of the breath samples  
In the first phase, we identified VOCs that could be useful as biomarkers in monitoring 
the response of a cancer to treatment. By GC-MS analysis, ~200 relevant VOCs were 
identified, all with main masses in the range of 33 to 282 m/z and retention times 
between 1.6 and 39.8 min.  Seventeen of these VOCs were found in >90% of the 
samples, with a similarity index >85%. Using these 17 VOCs, binary comparisons were 
conducted, as given above in detail under 'Methods', and summarized in Table 2: 
 
(i) DC (PR/SD) events after one cycle of therapy: Baseline samples vs. 
consecutive samples (i.e. first samples taken under treatment) of DC 
(PR + SD): 27 patients. 
(ii) PD events after one cycle of therapy: Baseline samples vs. 
consecutive samples of PD: 5 patients progressed immediately at the first 
sampling time. These were too few for a reliable comparison. 
(iii) PR vs. SD: 47 and 38 SD samples, respectively.  
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(iv) DC vs. PD: 85 PR+SD samples and 11 PD samples.  
 
The non-parametric Wilcoxon/Kruskal-Wallis test with a cutoff value of P=0.05 was 
used to find the significant VOCs. Three VOCs were identified as significant markers 
for DC for the first breath sample taken under treatment (Table 3), namely alpha-
phellandrene, styrene and dodecane-4-methyl. Styrene discriminated significantly 
between samples categorized as DC compared with PD. GC-MS analysis failed to 
show any significant discriminant VOCs between PR and SD cases.  
Nano-array analysis of the breath samples:  
In the second phase of the study, 131 breath samples were exposed to nano-array 
sensors, of which 4 samples were excluded for technical reasons. Thirty-eight were 
BL samples, 48 were PR, 34 were SD, and 11 were PD. 
We examined whether the sensor array could estimate and monitor tumor 
responsiveness to treatment, thereby alerting us about possible changes in tumor 
behavior. For this purpose, we developed 2 predictive models based on breath 
samples collected from 38 patients using DFA. Twenty-seven patients presented SD 
or PR at the first assessment, in whom the first DFA model attempted to identify 
disease control (DC samples) after the first treatment compared with the BL. This 
model showed a sensitivity of 93%, a specificity of 85% and an accuracy of 89% after 
leave-one-out cross-validation. The Positive Predicted Value (PPV) and Negative 
Predicted Value (NPV) for identification of DC were 86 and 92%, respectively.   
In the second DFA model, we distinguished 83 samples categorized as DC from 11 
samples categorized as PD. Despite achieving 100% specificity and 92% classification 
accuracy, the sensitivity was only 28%, whereas the PPV and NPV for identification of 
PD were 100 and 91%, respectively. Because of too few numbers of samples, we did 
not analyze patients who had PD in the first few cycles. 
 
Our main challenge was to monitor the single patient and be alerted to any change in 
the response to therapy, which could be achieved by using HBC-3 sensor. Figure 2 is 
a hot-plot in which each patient is represented in a separate row, and repeated breath 
samples are shown in separate columns. Each value has been normalized to the 
previous categorized sample. SD values for each categorization, set by calculating 
means and standard errors, were: (i) PD >0.15, (ii) -0.05 ≤ SD ≤ 0.05 and (iii) PR<-
0.05 (all units are given in ohm).   
10 
 
The hot-plot represents single-sensor analysis of 127 breath samples from 33 patients. 
Thirty-three of the samples were BL, and 94 were follow-up samples (49 PR, 34 SD, 
11 PD). Using one sensor, breath analysis correctly identified 59% of the PR (29/49), 
59% of the SD (20/34) and 54% of PD (6/11) samples. Altogether, 59% (55/94) of the 
follow-up samples were correctly identified.  For Disease Control, i.e. SD and PR 
together, there was an 85% success in response monitoring. There was no difference 
between different histological categories in this result.  
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DISCUSSION: 
The term "tumor response assessment" was introduced long ago in the medical 
literature. Miller et al. [31] as early as 1981 discussed the importance of creating a 
'common language' to be used in evaluating response to anti-cancer treatment. 
Numerous investigations of tumor response assessment have since been carried out 
in different types of cancer, including lung cancer [35]. Recent progress in cancer 
therapy has raised this challenge again, since response to immunotherapy and 
targeted therapy may now have to be judged on a different scale, as yet undefined. 
 
The World Health Organization (WHO) recommends response criteria for solid tumors, 
such as lung cancer, and proposes the use of the computed tomographic (CT) scan 
and endoscopy as methods to classify tumor response [36]. Along with the CT scan 
as the mainstay, advanced and novel imaging techniques are used to provide better 
information about tumor volume, perfusion and glucose uptake as potential biomarkers 
for tumor response and clinical outcome [35] . 
Nevertheless, although imaging remains the main method for objectively monitoring 
tumor response to treatment, it has some major disadvantages. The high cost and 
limited availability of imaging modalities, such as CT and CT/PET, preclude their use 
at short intervals for assessing patients' responses to treatment. According to the WHO 
recommendations, "progression in any site indicated disease progressions, despite 
objective responses in other sites" [36].  
 
Protein biomarkers, including CEA, CA125, CYFRA 21, NSE and ProGRP, can also 
be used in monitoring disease status [37], but this is only relevant when tumor markers 
are increased. Taking all these facts into consideration, a need for additional methods 
for monitoring tumor response to treatment becomes apparent, especially ones that 
enable closer follow-up and are more up-to-date in the bid for more reliable clinical 
decision making. 
 
This study indicates that exhaled-breath analysis may serve as a simple, user-friendly 
method of monitoring response to systemic therapy in lung cancer. Its particular 
importance is its potential to recognize failure very early on in the course of therapy 
before it becomes manifest by routine imaging schedules. This may help the physician 
to make better, more up-to-date, rational decisions regarding the cancer treatment 
selected for each patient. Likewise, in cases in remission (e.g. case #17 in Table 8 and 
Figure 5), exhaled breath may serve as a surrogate marker of disease recurrence.  
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Most importantly, both methodologies could recognize disease control within the first 
assessment, which is particularly important as it might avoid inefficient therapy that 
might have significant adverse effects.  
Conceptually, consecutive breath-samples would be collected from a patient at fixed 
times after receiving a cycle of anti-cancer treatment before initiating another cycle of 
therapy. Because of its simplicity, breath-collection can be done the physician’s  office. 
By using the signals received from the sensor-array, the physician could create a 
patient's personal 'hot-plot'(as in Figure 2). Its scale allows the physician to assess the 
patient's response to treatment and take appropriate clinical action. 
 
In this study, 2 powerful tools were used: (i) GC-MS. which is effective in the 
identification and quantification of human volatolomics. Gas chromatography 
separates VOCs according to their volatility, and the mass spectrometer determines 
their molecular mass and possible chemical structure. This method has some 
considerable limitations that preclude its wider use in clinical practice, including: 
expense, the need for pre-concentration techniques, a high level of expertise in its 
operation and analysis, and its time consuming nature. (ii) Nano-arrays. This 
approach uses a cross-reactive sensors array, each responding differently to all or part 
of the chemical compounds in an exhaled breath sample. By applying pattern 
recognition algorithms and classification techniques, the combined responses of the 
sensors can establish odor-specific response patterns without actually separating and 
identifying the specific VOCs responsible for causing the odor [38, 39]. 
 
Use of volatile biomarkers for monitoring response to treatment 
The source of the exhaled VOCs is not well understood [40]. We identified 3 VOCs as 
markers for response (Table 3). Several explanations have been published regarding 
their formation.  
Styrene is an aromatic compound used in manufacturing of plastics, synthetic rubber 
and resins that is considered to be an exogenous pollutant. Other exogenous sources 
include tobacco smoke, alcohol, other types of pollution and radiation. The IARC 
classifies styrene as a possible carcinogen to humans [41]. Since aromatic compounds 
can be highly reactive, they can be taken up into the cytoplasm, attacking tissues and 
organs in the body by causing peroxidation damage to proteins, polyunsaturated fatty 
acids (PUFA) and DNA. This damage accumulates during the lifetime, possibly leading 
to age-dependent diseases, such as cancer, and products from it may be released 
slowly into the breath [42] .  
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a-Phellandrene (a-PA; 5-isopropyl-2-methyl-1,3-cyclohexadiene) is a cyclic 
unsaturated monoterpene formed from essential oils of many edible plants or herbs. 
Dodecane, 4-methyl is a branched-chain alkane.  
The main mechanism affecting the emission of hydrocarbons in the body is oxidative 
stress, which is defined as the overall balance between formation and scavenging of 
reactive oxygen species (ROS) and free radicals in the body. ROS are molecules or 
ions with unpaired electrons in the outer shell, which are constantly being produced in 
the mitochondria as part of cellular respiration. They can also be produced by fungal 
and viral infections, or stem from exogenous sources, such as cigarette smoke, 
pollution and radiation [40] .  
The hypothesis that various VOCs have different origins in the body could explain the 
different changes in concentration between the VOCs in response to anti-cancer 
treatment. For example, some VOCs can be produced locally within the tumor or its 
microenvironment; their concentration VOCs would be expected to drop if there is a 
positive response to treatment and a reduction in tumor volume, but to rise with disease 
progression. Other VOCs might be produced as a result of systemic changes induced 
by presence of a cancer, and changes in concentration would therefore be expected 
to take longer to be expressed in the breath. On the other hand, some VOCs might be 
released from tumors cells undergoing necrosis, such that their concentration might 
rise in the case of a positive response to treatment. 
Taking everything into consideration, identification of specific VOCs that change in 
concentration as a result of changes in the cancerous disease may point the goal 
towards more precise, focused research in the future, hopefully with larger sample 
size. Styrene appears to be the most interesting VOC in our study, being the only one 
that showed significant changes in concentration in both comparisons (Baseline 
samples vs. DC, and DC vs. PD). In both cases, the concentration of styrene was lower 
in the DC group, suggesting that a decrease in the concentration of styrene in 
exhaled breath can indicate a positive response to treatment. This tendency of a 
lower concentration of styrene associated with improvement in the cancerous disease 
has already been noted [29, 40]. As most of our cohort responded during the first few 
cycles, our upfront PD group was too small to investigate the level of this VOC 
compared with baseline samples, an interesting issue requiring futher investigation.   
 
Use of sensor-array for evaluation of treatment response 
The sensor-array analysis provides an easier and more intuitive indication. Analysis 
achieved a relatively high accuracy in the 2 sets of classifications. The first DFA model 
(see 'Methods') took into consideration patients who had reached disease control after 
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the initial treatment (i.e. SD or PR). Their baseline samples compared with their 
subsequent samples showed a relatively high classification capability (93% sensitivity 
and 85% specificity). The second DFA model compared PR/SD samples with 
subsequent PD status; the specificity (true negative value) in this model was 100%, 
but the sensitivity was only 28%, indicating that it is highly reliable in detecting negative 
progression of the disease and lack of response to treatment (PD states).  
 
In practice, these results indicate that the physician can predict a positive response to 
treatment starting from the first session with a PPV of 86%. Following initial 
assessment, the physician can use sensor set 2 to test whether the patient had a 
positive response (PR/SD) or did not respond to treatment, i.e. the disease had 
progressed (PD). In this case, the PPV was 100%, implying that identification of a 
sample as PD is 100% trustworthy. These are only preliminary results that require a 
larger study group for validation; nevertheless, the results support the potential use of 
the NA-NOSE as a monitoring tool and show its ability to discriminate between 
response and lack of response to anti-cancer treatment. 
The attempt to use only one sensor in monitoring the response to treatment led to an 
interesting pattern presented as a hot-plot in Figure 2, which displays each patient 
separately. Each sample is normalized to the previous sample from the same patient, 
and is colored according to the resistance of the sensor for the specific sample. If one 
assumes correct identification in achieving Disease Control (SD+PR) vs. lack of 
response to treatment (PD), 85% percent of the cases were identified and colored 
correctly by the single sensor (HBC-3). There may be several explanations regarding 
the cases that were wrongly identified. First, some cases could have been categorized 
wrongly, mainly because sometimes the true volume or progression of the cancer is 
not well represented in the CT scans - either the changes might still be too small to 
trace, or a new tumor focus exists in a part of the body that was not scanned and 
therefore was not recognized. In such cases, samples categorized as PR/SD might 
actually be PD. In the same way, a sample categorized as SD might actually be PR if 
a positive response to treatment has been detected by the sensor, but not as yet by 
the CT scan. A second possibility is that, in this hot-plot, each sample is normalized to 
the previous one; but in some cases, the time-interval between the 2 samples has 
been too long (due to clinical reasons, e.g. prolonged lack of evidence of disease), and 
normalization then gives an inaccurate result.  
 
Future potential and clinical applications 
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GC-MS has many disadvantages such as being time-consuming, costly, requiring 
cumbersome equipment and specialized knowledge in order to analyze the results. 
Therefore, the nano-array method is a more realistic option for use in clinical practice 
in the future, requiring only compact and easy to use equipment, and does not require 
pre-concentration and/or dehumidification procedures. The sensors are broadly cross-
reactive, respond to a wide range of compounds, and are less affected by noise than 
the detected (sub) ppb-ppm concentrations of the compounds identified by the GC-
MS. Moreover, the sensors can be tuned to show very low sensitivity to confounding 
VOCs from the surroundings, whereas the GC-MS detects these confounding VOCs, 
thereby introducing noise into the measurement of the compounds of interest, which 
is likely to affect the overall accuracy of the method [5, 6, 16, 29] . 
 
The limitations of this study include a relatively small cohort group. However, we had 
a total of 143 comparisons and an internal longitudinal monitoring was also used for 
all the patients, with a longest period of 14 months.  We enrolled patients under range 
of treatments, including chemotherapies and targeted therapies. We assume that 
tumor death produces most of the volatile signature,  breath sampling being done 3 
weeks from the most recent cycle, i.e. away from the direct effect of the drug.  
Focusing on subgroup analysis, we managed to distinguish SCLC from NSCLC with 
100% sensitivity and 94% specificity (95% accuracy); adenocarcinoma from 
squamous cell with 75% sensitivity and 95% specificity (92% accuracy); mutation vs. 
non-mutation with 90% sensitivity and 50% specificity (81% accuracy). These are 
interesting and valid results; however, they do not reflect the need of sub-division of 
the results in assessing the use of breath sampling in monitoring response to anti-
cancer treatment. Due to small sample size, we unfortunately were unable to draw a 
surrogate model for every subgroup.  
In summary, standardization of assessment in tumor responsiveness is important in 
allowing effective comparisons between results of different cancer treatments. As 
strongly rooted in the clinical 'language', we expect RECIST to remain the primary 
criteria for the assessment of response to treatment in cancer patients, with advanced 
and novel monitoring techniques being used as adjuncts. This study offers a proof-of-
concept of the idea that exhaled breath can provide a new modality in monitoring the 
response to anti-cancer treatment in patients with advanced lung cancer. It can help 
to define disease progression during conventional chemotherapy, molecular targeted 
therapy, or both. Monitoring tumor response to treatment during shorter intervals than 
currently available by CT scans should allow earlier decision-making regarding the 
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chosen treatment.  We believe that future research of exhaled breath analysis will yield 
excellent results that pave the way to using VOCs as markers for cancer diseases and 
for monitoring disease progression. Ideally, further studies require a larger study group 
and closer follow-up, which will give a more precise categorization of breath samples 
and statistically stronger results.  
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LEGENDS: 
Figure 1: Graphic representation of breath sampling and analysis procedure.  (A) 
collection of the breath sample in a single-step process into a chemically inert Mylar 
bag; (B) Transfer of the bag content to Tenax® sorbent tube; (C) Thermal Desorption 
to release the VOCs from the sorbent tube; (D) GC-MS to detect and analyze the 
compounds; (E) Sensor array containing Gold Nano Particles (GNPs) with different 
modifications and Poly Aromatic Hydrocarbons (PAH). 
 
Figure 2:  Hot-plot for the follow-up of LC states. Patients are represented by the rows 
and columns give successive breath samples for each patient. The scale represents 
the normalized resistance of the sensor, as described before, and units are given in 
ohms. Samples not identified by the sensor are marked by black blocks. The red tones 
in the color scale represent increased resistance of the sensor, indicating a worsening 
of the disease, whereas the green tones represent a decrease in resistance of the 
sensor and indicate a positive response to treatment.   
 
Table 1: Summary of personal clinical data (N=39) 
Gender Male 31 (80%)   
 Female 8 (20%)   
Age (years) Range 36-84   
 mean (SD) 62 (±10.7)   
BMI (kg/m²) Mean (SD) 24.5 (±4.3)   
Smoking status Never 5 (13%)   
 Previous 27 (69%) PY: 52 (±24)  
 Current 7 (18%) PY:  86 (±54)  
Histology Non-small-cell 
lung carcinoma 
33 (85%) Adenocarcinoma 
Squamous carcinoma  
24 (73%) 
4 (12%) 
   Not Otherwise 
Specified 
5 (15%) 
 small-cell lung 
carcinoma 
6 (15%) All Extensive SCLC  
EGFR mutation 7 (18%)    
ALK fusion 1(2.5%)    
Stage  3A 6 (15%)   
 3B 3 (8%)   
 4 30 (77%)   
 
 
 
 
 
 
 
 
 
 
 
Table 2: Categorization of breath samples 
Group 
Number of  events 
(& breath samples) 
after one cycle of 
therapy  
Total number of 
follow up events (& 
breath samples) 
Baseline sample  39 
Partial response (PR) 17 47 
Stable disease (SD) 10 38 
Progressive disease (PD) 5 11 
TOTAL no. of breath samples  135 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3: VOCs from exhaled breath samples that discriminated significantly (p < 
0.05) between the Baseline and DC groups and between DC and PD groups.  
Retention 
time[min] m/z 
Chemical 
group 
CAS 
no. 
VOC 
name 
 
 
BL 
(abundance + 
stderr) 
 
 
PD 
(abundance+ 
stderr) 
 
 
PR 
(abundance + 
stderr) 
 
 
SD 
(abundance + 
stderr) 
P-values 
(Wilcoxon non-
parametric 
method) 
Baseline 
vs. DC 
PD  
vs. 
DC 
25.6 93 Alicyclic Hydrocarbons 99-83-2 
alpha.-
Phellandrene 
 22043.8±3529.8 9960±2098.4 13673±1975.2 18206±3001.5 
0.0075* 
↓a - 
20.3 104 Aromatic compound 100-42-5 Styrene  372346.1±59623.1 425657.8±91750.3 241379.8±34337.2 247320.8±41220.1 0.0241* ↓ 0.0263* ↓ 
29.2 71 Branched Alkanes 6117-97-1 
Dodecane, 
4-methyl 
 17166.3±2748.8 7791.3±1318.4 11883.23±1234.11 13685.5±2280.917 
0.0105* 
↓ - 
 
a   In breath analysis: a lower concentration of a VOC appears in the breath of DC samples compared to BL samples.  
b  In breath analysis: a lower concentration of a VOC appears in the breath of DC samples, compared to PD samples. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4: Statistical classification success, using DFA and cross validation 
  BL vs. PR+SD  PR+SD vs. PD 
  PR+SD=positive 
 BL = negative 
PD= positive 
PR+SD = negative 
  Sensor set 1  Sensor set 2 
True positive  25	 3	
True negative  23	 83	
False positive  4	 0	
False negative  2	 8	
Sensitivity a (%)  93	 28	
Specificity b (%)  85	 100	
Accuracy c (%)  89	 92	
PPV (%)  86	 100	
NPV (%)  92	 91	
 
aSensitivity=TP/(TP+FN). 
bSpecificity=TN/(TN+FP). 
cAccuracy=TP+TN/(TP+TN+FN+FP). 
dPPV - Positive predictive value =TP/(TP+FP). 
eNPV - Negative predictive value = TN/( TN+FN). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5: Selected example of consecutive CT scans for patient #17 in the study 
(73 years old; SCLC), with the corresponding breath samples and NA-NOSE 
sensors' resistance (given in ohm). 
     
CT scan 
24/03/2013 03/02/2013 23/12/2012 08/08/2012 07/03/2012 Date of 
CT 
02/04/2013 07/03/2013 21/11/2012 16/08/2012 05/04/2012 Date of 
breath 
sample 
SD PR PD PR Baseline 
sample* 
Response 
to 
treatment 
0.788115 1.069338 2.761164 0.861627 1.252173 NA-
NOSE 
(sensor's 
resistance 
[ohm]) 
*before initiation of treatment  
PD- progressive disease, PR- partial response, SD- stable disease 
 
 
 
